Botulinum Toxin Therapy in Hidradenitis Suppurativa
Purpose
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.
Conditions
- Hidradenitis Suppurativa
- Hyperhidrosis
Eligibility
- Eligible Ages
- Between 18 Years and 75 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion:
- Adults between ages 18 and 75 years with established diagnosis of hidradenitis
suppurativa (HS)
- HS skin lesions of duration at least 1 year, HS skin lesions in at least two
different body areas
Exclusion:
- Age < 18 years or > 75 years
- pregnant or breastfeeding
- neuromuscular disorder (ex. ALS, myasthenia gravis, Lambert-Eaton syndrome,
myopathy)
- medical co-morbidity that is a relative contraindication to skin biopsy procedure
(ex. end stage congestive heart failure or coagulopathy)
- active bacterial, fungal, or viral infection in the treatment area
- known hypersensitivity to botulinum toxin A preparations or any of their components
(human albumin, saline, lactose, sodium succinate)
- prisoners
- adults unable to consent for themselves.
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Case-Only
- Time Perspective
- Prospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| single group assignment | men or women between the ages of 18-75 who have an established diagnosis of Hidradenitis Suppurativa |
|
Recruiting Locations
Worcester, Massachusetts 01605
More Details
- Status
- Recruiting
- Sponsor
- University of Massachusetts, Worcester
Detailed Description
Botulinum toxin prevents vesicle fusion at nerve terminals thereby inhibiting neuropeptide release. The investigators will collect punch biopsies of lesional skin from HS patients before, and 1-2 months after botulinum toxin treatment (50U per axilla in 10 injections of 0.1mL) then perform flow cytometric, transcriptomic, and microscopic analysis of skin to determine if nonselective inhibition of neuropeptide release diminishes IL-17 driven skin inflammation.